Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$37.71 -1.2%	$37.12	$23.42 ▼ $62.58	$2.22B	0.8	936,872 shs	502,787 shs
ARVN Arvinas	$7.73 -0.4%	$7.48	$5.90 ▼ $29.61	$569.72M	2.22	1.93 million shs	735,457 shs
HRMY Harmony Biosciences	$36.89 -2.8%	$34.98	$26.47 ▼ $41.61	$2.18B	0.84	522,924 shs	474,415 shs
IDYA IDEAYA Biosciences	$24.55 -1.5%	$23.26	$13.45 ▼ $40.25	$2.18B	0.09	877,057 shs	632,810 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-2.78%	-0.05%	+1.19%	+17.88%	-15.83%
ARVN Arvinas	-3.96%	+6.30%	+3.74%	+7.33%	-69.89%
HRMY Harmony Biosciences	-0.21%	+1.82%	+7.11%	+10.44%	+7.08%
IDYA IDEAYA Biosciences	-0.28%	+1.22%	+0.36%	+24.34%	-37.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3618 of 5 stars	3.4	2.0	4.3	3.2	0.8	1.9
ARVN Arvinas	3.9305 of 5 stars	4.3	3.0	0.0	3.0	2.5	1.3
HRMY Harmony Biosciences	4.6478 of 5 stars	3.5	3.0	0.0	3.0	3.3	4.4
IDYA IDEAYA Biosciences	4.5051 of 5 stars	4.4	3.0	4.4	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	49.39% Upside
ARVN Arvinas	2.55	Moderate Buy	$19.76	155.67% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.00	38.25% Upside
IDYA IDEAYA Biosciences	2.75	Moderate Buy	$47.10	91.85% Upside

Current Analyst Ratings Breakdown

Latest ARVN, IDYA, AGIO, and HRMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $18.00
8/7/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $16.00
8/7/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$66.00 ➝ $72.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/22/2025	IDYA IDEAYA Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/21/2025	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$48.00
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$33.00
7/10/2025	IDYA IDEAYA Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$25.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	60.03	N/A	N/A	$23.57 per share	1.60
ARVN Arvinas	$263.40M	2.15	N/A	N/A	$8.30 per share	0.93
HRMY Harmony Biosciences	$714.73M	2.97	$2.86 per share	12.89	$13.44 per share	2.74
IDYA IDEAYA Biosciences	$7M	307.37	N/A	N/A	$10.95 per share	2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.43	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
ARVN Arvinas	-$198.90M	-$1.01	N/A	N/A	N/A	-19.47%	-12.01%	-6.97%	10/29/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$3.10	11.90	11.86	0.44	23.44%	26.34%	17.71%	11/4/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.79	N/A	N/A	N/A	N/A	-31.42%	-29.45%	11/3/2025 (Estimated)

Latest ARVN, IDYA, AGIO, and HRMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	-$0.84	+$0.03	-$0.84	$34.42 million	$22.40 million
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	$0.68	-$0.10	$0.68	$204.37 million	$200.49 million
8/5/2025	Q2 2025	IDYA IDEAYA Biosciences	-$0.85	-$0.88	-$0.03	-$0.88	$3.48 million	$6.00 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
ARVN Arvinas	N/A	5.64	5.64
HRMY Harmony Biosciences	0.20	3.84	3.80
IDYA IDEAYA Biosciences	N/A	12.39	12.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ARVN Arvinas	95.19%
HRMY Harmony Biosciences	86.23%
IDYA IDEAYA Biosciences	98.29%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
ARVN Arvinas	4.73%
HRMY Harmony Biosciences	23.60%
IDYA IDEAYA Biosciences	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
ARVN Arvinas	420	73.42 million	69.95 million	Optionable
HRMY Harmony Biosciences	200	57.53 million	43.96 million	Optionable
IDYA IDEAYA Biosciences	80	87.64 million	85.45 million	Optionable

ARVN, IDYA, AGIO, and HRMY Headlines

Recent News About These Companies

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

August 29 at 2:00 PM | prnewswire.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 29 at 6:00 AM | prnewswire.com

IDEAYA Biosciences, Inc. $IDYA Shares Bought by Jump Financial LLC

August 29 at 5:19 AM | marketbeat.com

AlphaQuest LLC Boosts Stake in IDEAYA Biosciences, Inc. $IDYA

August 29 at 4:57 AM | marketbeat.com

Price T Rowe Associates Inc. MD Reduces Stock Position in IDEAYA Biosciences, Inc. $IDYA

August 29 at 4:06 AM | marketbeat.com

Nuveen LLC Acquires New Holdings in IDEAYA Biosciences, Inc. $IDYA

August 29 at 3:36 AM | marketbeat.com

Vanguard Group Inc. Purchases 14,535 Shares of IDEAYA Biosciences, Inc. $IDYA

August 26 at 3:04 AM | marketbeat.com

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

August 25, 2025 | prnewswire.com

Candriam S.C.A. Trims Stock Position in IDEAYA Biosciences, Inc. $IDYA

August 23, 2025 | marketbeat.com

Aberdeen Group plc Boosts Stock Holdings in IDEAYA Biosciences, Inc. $IDYA

August 23, 2025 | marketbeat.com

Algert Global LLC Acquires Shares of 306,708 IDEAYA Biosciences, Inc. $IDYA

August 21, 2025 | marketbeat.com

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

August 18, 2025 | prnewswire.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Deutsche Bank AG

August 17, 2025 | marketbeat.com

RBC Capital Remains a Buy on IDEAYA Biosciences (IDYA)

August 11, 2025 | theglobeandmail.com

Leerink Partnrs Has Bullish Estimate for IDYA Q3 Earnings

August 11, 2025 | marketbeat.com

FY2025 EPS Estimates for IDYA Cut by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

XTX Topco Ltd Acquires 17,536 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

August 9, 2025 | marketbeat.com

Q3 EPS Forecast for IDEAYA Biosciences Increased by Analyst

August 8, 2025 | marketbeat.com

GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959

August 7, 2025 | msn.com

IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS

August 6, 2025 | marketbeat.com

Ideaya Biosciences: Moving Into ADCs For Solid Tumors

August 6, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, IDYA, AGIO, and HRMY Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$37.71 -0.47 (-1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$37.72 +0.02 (+0.04%)

As of 05:38 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Arvinas NASDAQ:ARVN

$7.73 -0.03 (-0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$7.72 -0.01 (-0.06%)

As of 07:27 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Harmony Biosciences NASDAQ:HRMY

$36.89 -1.08 (-2.84%)

Closing price 04:00 PM Eastern

Extended Trading

$37.00 +0.11 (+0.30%)

As of 06:10 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

IDEAYA Biosciences NASDAQ:IDYA

$24.55 -0.38 (-1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$24.47 -0.08 (-0.33%)

As of 05:43 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time